- Report
- August 2024
- 170 Pages
Global
From €4139EUR$4,500USD£3,501GBP
- Report
- July 2024
- 150 Pages
Global
From €3449EUR$3,750USD£2,917GBP
- Report
- May 2024
- 138 Pages
Global
From €5977EUR$6,499USD£5,056GBP
- Report
- November 2023
- 432 Pages
Global
From €8737EUR$9,500USD£7,391GBP
- Report
- November 2023
- 230 Pages
Global
From €6898EUR$7,500USD£5,835GBP
- Report
- January 2022
- 160 Pages
Global
From €8737EUR$9,500USD£7,391GBP
- Report
- February 2024
- 110 Pages
Global
From €4369EUR$4,750USD£3,695GBP
- Report
- January 2022
- 112 Pages
Global
From €4369EUR$4,750USD£3,695GBP
- Report
- August 2019
- 212 Pages
Global
From €13791EUR$14,995USD£11,666GBP
- Report
- January 2021
- 124 Pages
Global
From €3311EUR$3,600USD£2,801GBP
- Report
- January 2024
- 129 Pages
United States
€3495EUR$3,800USD£2,956GBP
Darolutamide is a novel androgen receptor inhibitor used in the treatment of prostate cancer. It is a non-steroidal anti-androgen that works by blocking the action of androgens, such as testosterone, in the body. Darolutamide is used in combination with other drugs to treat advanced prostate cancer that has spread to other parts of the body. It is also used to delay the progression of the disease in men who have not yet received chemotherapy. Darolutamide is taken orally, usually twice a day.
Darolutamide is a relatively new drug in the prostate cancer market, but it has been gaining traction due to its efficacy and safety profile. It has been shown to be well tolerated and to have fewer side effects than other drugs used to treat prostate cancer.
Some companies in the Darolutamide market include Bayer, Astellas Pharma, and Orion Corporation. Show Less Read more
